albumin-bound paclitaxel
Phase 3Small molecule
Bristol-Myers Squibbalbumin-bound paclitaxel is one of 538 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 3.
27
Indications
74
Total Trials
40
Active Trials
537
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 27 indications
Competition
Competitive Landscape
706 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1albumin-bound paclitaxel
Bristol-Myers SquibbPhase 3
Adenocard
AstellasPreclinical
Lexiscan
AstellasPreclinical
Voltaren
NovartisPreclinical
Zolymbus
AbbViePreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer12 trials
Show 9 more trials
Pancreatic Cancer6 trials
Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 4·NCT05035147·934 enrolled
Show 3 more trials
A Multi-cohort Exploratory Study to Evaluate the Efficacy and Safety of Albumin-bound Paclitaxel (Ⅱ)-Combined Regimens for Pancreatic Cancer
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07828756·147 enrolled
Gastric Cancer5 trials
Show 2 more trials
Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis
Enrolling by invitation·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT06487715·42 enrolled
Esophageal Squamous Cell Carcinoma4 trials
Esophageal Cancer3 trials
Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer
Completed·—·Phase 2·NCT04821765·35 enrolled
Chemoradiotherapy in Unresectable Esophageal Cancer
Recruiting·—·Phase 1/2·NCT04278287·105 enrolled
36 more indications
Non-Small Cell Lung Cancer2 trials
Advanced Solid Tumors2 trials
HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors
Recruiting·—·Phase 1/2·NCT05681650·30 enrolled
Adenocarcinoma2 trials
Cervical Cancer2 trials
Second-line Treatment2 trials
Advanced/Metastatic Solid Tumors2 trials
CD73/AXL Targeted HypoSti.CAR-T Cells in CD73/AXL Positive Advanced/Metastatic Solid Tumors
Not yet recruiting·—·Phase 1/2·NCT06939270·30 enrolled
Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors
Recruiting·—·Phase 1/2·NCT05693844·15 enrolled
Nasopharyngeal Carcinoma2 trials
Paclitaxel (Albumin-bound) Combined With Radiotherapy for the Treatment of Early Stage Nasopharyngeal Carcinoma
Unknown status·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 3·NCT04766359·364 enrolled
Patients With Advanced Solid Tumors2 trials
Neoadjuvant Chemoimmunotherapy1 trial
Soft Tissue Sarcoma1 trial
Esophageal Squamous Carcinoma1 trial
Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma
Not yet recruiting·TThe First Affiliated Hospital of Xiamen University·Phase 2·NCT07019181·26 enrolled
Penile Cancer1 trial
Head and Neck Squamous Cell Carcinoma1 trial
Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)
Not yet recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 3·NCT06647563·355 enrolled
Urothelial Carcinoma1 trial
Pancreatic Ductal Adenocarcinoma1 trial
Ovarian Cancer1 trial
Lung Cancer1 trial
Paclitaxel1 trial
Resectable NSCLC1 trial
Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE）
Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT04459611·60 enrolled
Neoadjuvant Treatment1 trial
Head and Neck1 trial
Oropharyngeal Cancer1 trial
Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)
Active, not recruiting·—·Phase 2·NCT06009861·110 enrolled
Immunotherapy1 trial
Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC
Recruiting·—·Phase 2·NCT06725498·50 enrolled
Nab-paclitaxel1 trial
Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma
Unknown status·—·N/A·NCT04443036·44 enrolled
Neoadjuvant Chemotherapy1 trial
Effect of Albumin-bound Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Patients Receiving Neoadjuvant Chemotherapy for Advanced Ovarian, Fallopian Tube or Peritoneal Cancer: A Phase 2 Single Center Clinical Trial
Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT05316376·78 enrolled
Melanoma, Cutaneous Malignant1 trial
Advanced Cancer1 trial
A Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of TST001 Administered as Monotherapy or in Combination With Nivolumab or Standard of Care in Patients With Locally Advanced or Metastatic Solid Tumors
Active, not recruiting·SSuzhou Transcenta Therapeutics Co., Ltd.·Preclinical·NCT04396821·150 enrolled
Triple-Negative Breast Cancer1 trial
A Prospective, Randomized, Open Label Clinical Study Evaluating Efficacy and Safety of Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic Triple Negative Breast Cancer
Recruiting·TThe First Affiliated Hospital of Bengbu Medical University·Phase 2·NCT05192798·128 enrolled
GC/GEJC1 trial
Solid Tumor1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for albumin-bound paclitaxel. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company